GO
Loading...

Biotechnology

More

  • Eli Lilly to Buy SGX Pharmaceuticals for $64 Million Tuesday, 8 Jul 2008 | 6:52 PM ET

    Drug developer Eli Lilly will buy SGX Pharmaceuticals for about $64 million in cash in an effort to expand its drug discovery efforts, the companies said Tuesday.

  • Win With Genentech Against the Bears Monday, 7 Jul 2008 | 11:18 PM ET

    Cramer continued with his "Cramerican Marine Field Guide to Recessions" reflecting on the 1990 Playbook (the last time we had a financial meltdown) where healthcare stocks, especially biotech were the winners then, and in Cramer's view are likely to do it again.

  • How to Play the Recession Game Monday, 7 Jul 2008 | 7:25 PM ET

    Cramer tells what works in the Wall Street fashion show, what gets the big money guys to turn their heads and say, “ah, I want to own that right now,” or "I want to dump that right now", for the exact  situation we’re facing.

  • Stop Trading!: Buy Biotech? Monday, 30 Jun 2008 | 3:22 PM ET

    That's what worked in 1990, in an environment much like this one.

  • Liposuction Without the Surgery Friday, 20 Jun 2008 | 6:31 PM ET

    Medicis Pharma could have such a product on the market by 2011.

  • Stop Trading!: Buy Yum! Brands Thursday, 5 Jun 2008 | 3:28 PM ET

    Plus, two more international stock picks from Cramer.

  • Antigenics Finds That "Russian Roulette" Pays Off Tuesday, 8 Apr 2008 | 10:31 AM ET

    This morning a little biotech company, Antigenics, announced that Russia has approved its kidney cancer drug Oncophage. It's the first so-called therapeutic cancer vaccine to win full-out approval anywhere in the world.

  • Lightning Round: Celgene, Apple, Chevron and More Tuesday, 25 Mar 2008 | 7:09 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • Lightning Round: Medco, Amgen, Yum! and More Thursday, 28 Feb 2008 | 8:12 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • Fund Manager: Buy Fast -- and Buy These Names Tuesday, 26 Feb 2008 | 3:29 PM ET

    The time to buy stocks, says Michael Cuggino, is now. The president and portfolio manager of Permanent Portfolio Funds offered CNBC very specific reasons to buy -- and the specific stocks you need.

  • Lightning Round: Loews, NYSE, Tesco and More Tuesday, 15 Jan 2008 | 3:39 PM ET

    Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Outsourcing Is Good – for Investors Tuesday, 15 Jan 2008 | 3:37 PM ET

    To politicians, railing against it brings votes. To companies, it cuts costs. But to Cramer, it’s a chance to make Homegamers some mad money.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • FDA Set to OK Cloned Meat: WSJ Friday, 4 Jan 2008 | 3:36 AM ET

    The Food and Drug Administration is expected to declare as early as next week that meat and milk from cloned animals and their offspring are safe to consume, the Wall Street Journal reported without naming its source.

  • What Went Wrong in 2007 Thursday, 3 Jan 2008 | 11:06 AM ET

    Cramer’s New Year’s resolution: never to make these mistakes again.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Trade Options 'Like an Insider' (Legally) Tuesday, 18 Dec 2007 | 12:40 PM ET

    You can trade legally options "like an insider" -- if you stay alert and watch market momentum. Jon Najarian, co-founder of OptionsMonster.com and frequent guest on CNBC's "Fast Money," offered his wisdom on how to do it -- and which options look the hottest right now.

  • Genentech Drug Toxicity Under FDA's Microscope Monday, 3 Dec 2007 | 11:37 AM ET
    Genetech

    The benefits of Genentech's cancer drug Avastin in breast cancer should be weighed against some toxic side effects, including the potential for death, U.S. regulatory staffers said in documents released Monday.

  • Fund Manager Names Overlooked Mid-Cap Stocks Friday, 30 Nov 2007 | 4:05 PM ET

    Mid-cap stocks may be often overlooked -- but they can make an investor a lot of money, says Tony Dong, the portfolio manager of Munder Mid-Cap Core Growth Fund. He offered stock picks with low profiles and high potential.

  • US Panel Backs Abbott's Drug-Coated Heart Stent Thursday, 29 Nov 2007 | 9:18 PM ET

    Abbott Laboratories moved closer to joining the U.S. market for drug-coated heart stents on Thursday as an advisory panel backed the company's experimental device.

  • For a Monday before the Thanksgiving holiday, this is turning into an extremely busy day on the biotech beat. Two of the stories actually broke on Sunday: Celgene buying Pharmion for nearly $3 billion and Genentech announcing a breakthrough in brain cancer. Then, before the opening bell this morning Onyx Pharmaceuticals and Bayer won the expected Food and Drug Administration approval of their drug Nexavar for liver cancer.

  • Back To Biotech: Risk & Reward Wednesday, 14 Nov 2007 | 11:06 AM ET

    In 1990, Amgen was the risky-but-profitable biotech of choice. Today, its stand-in is Onyx Pharmaceuticals.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.